Coherus BioSciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders held by Coherus BioSciences, Inc. on May 22, 2019. The record date for the meeting was March 29, 2019, with 69,338,697 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Two proposals were submitted to a vote of security holders:
- Proposal 1: Election of Class II Directors. Stockholders elected three nominees to the Board of Directors to serve until the 2022 Annual Meeting. A total of 52,673,489 shares were voted on this proposal.
- Samuel Nussbaum, M.D.: 45,138,007 For, 343,987 Withheld, 7,191,495 Broker Non-Votes.
- Mary T. Szela: 44,660,361 For, 821,633 Withheld, 7,191,495 Broker Non-Votes.
- Ali J. Satvat: 45,136,232 For, 345,762 Withheld, 7,191,495 Broker Non-Votes.
- Proposal 2: Ratification of Independent Auditor. Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- Results: 52,588,990 For, 79,451 Against, 5,048 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the three Class II director nominees were successfully elected to the Board.
- Verification that Ernst & Young LLP was ratified as the independent auditor for the 2019 fiscal year.
- Review of the Definitive Proxy Statement on Schedule 14A (filed April 10, 2019) for detailed background on the nominees and auditor selection.